nach oben

Inflammation Research

Erschienen in:

01.06.2011 | Original Research Paper

Anti-inflammatory effects of ivermectin in mouse model of allergic asthma

verfasst von: Shuhan Yan, Xinxin Ci, Na Chen, Chi Chen, Xiangchao Li, Xiao Chu, Jianhua Li, Xuming Deng

Erschienen in: Inflammation Research | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Asthma is an inflammatory disease of the lungs that is characterised by increased inflammatory cell infiltration into the airways and poor respiratory function. Ivermectin is a semi-synthetic derivative of a family of macrocyclic lactones that shows broad-spectrum anti-parasitic activity. This drug has been shown to possess anti-inflammatory activity, but whether it can be used in asthma treatment has not yet been investigated. In this study, we aimed to investigate the inhibitory effects of ivermectin on allergic asthma symptoms in mice.

Methods and results

We used a mouse asthma model, in which allergic airway inflammation and airway remodelling were induced by ovalbumin (OVA) sensitisation and challenge. Ivermectin or PBS treatment was administered 1 h before OVA challenge. Ivermectin at 2 mg/kg significantly diminished recruitment of immune cells, production of cytokines in the bronchoalveolar lavage fluids and secretion of OVA-specific IgE and IgG1 in the serum. Histological studies indicated that ivermectin suppressed mucus hypersecretion by goblet cells in the airway.

Conclusions

This is the first study to demonstrate that ivermectin is an effective suppressor of inflammation and may be efficacious in the treatment of non-infectious airway inflammatory diseases such as allergic asthma.

Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z. New insights into the pathogenesis of asthma. J Clin Invest. 2003;111:291–7.PubMed

Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. Annu Rev Immunol. 1999;17:255–81.PubMedCrossRef

Anderson GP, Coyle AJ. Th2 and ‘Th2-like’ cells in allergy and asthma: pharmacological perspectives. Trends Pharmacol Sci. 1994;15:324–32.PubMedCrossRef

Braman SS. The global burden of asthma. Chest. 2006;130:4–12.CrossRef

Bryskier A, Agouridas C, Chantot JF. New medical targets for macrolides. Exp Opin Invest Drugs. 1994;3:405–10.CrossRef

Tarayre JP, Aliaga M, Barbara M, Villanova G, Ballester R, Tisne-Versailles J, et al. Cutaneously applied erythromycin base reduces various types of inflammatory reactions in mouse ear. Int J Tiss Reac. 1987;4:77–85.

Mikasa K, Kita E, Sawaki M, Kunimatsu M, Hamada K, Konishi M, et al. The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice. J Antimicrob Chemother. 1992;30:339–48.PubMedCrossRef

Agen C, Danesi R, Blandizzi C, Costa M, Stacchini B, Favini P, et al. Macrolide antibiotics as antiinflammatory agents: roxithromycin in an unexpected role. Agents Actions. 1993;38:85–90.PubMedCrossRef

Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31:12–20.PubMedCrossRef

10.

Hrvačić B, Bošnjak B, Bosnar M, Ferenčić Ž, Glojnarić I, Eraković Haber V. Clarithromycin suppresses airway hyperresponsiveness and inflammation in mouse models of asthma. Eur J Pharmacol. 2009;15:236–43.

11.

Beigelman A, Gunsten S, Mikols CL, Vidavsky I, Cannon CL, Brody SL, et al. Azithromycin attenuates airway inflammation in a noninfectious mouse model of allergic asthma. Chest. 2009;136(2):498–506.PubMedCrossRef

12.

Caumes E, Danis M. New indications of ivermectin. Rev Med Interne. 2001;22:379–84.PubMedCrossRef

13.

Stankiewicz M, Cabaj W, Jonas WE, Moore LG, Millar K, Ng Chie W. Influence of ivermectin on cellular and humoral immune responses of lambs. Vet Immunol Immunopathol. 1995;44:347–58.PubMedCrossRef

14.

Zhang X, Song Y, Xiong H, Ci X, Li H, Yu L, et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E₂ production in LPS-stimulated RAW 264.7 macrophages. Int J Immunopharmacol. 2009;9:354–9.CrossRef

15.

Zhang X, Song Y, Ci X, An N, Ju Y, Li H, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57:524–9.PubMedCrossRef

16.

Van Rijt LS, Kuipers H, Vos N, Hijdra D, Hoogsteden HC, Lambrecht BN. A rapid flow cytometric method for determining the cellular composition of bronchoalveolar lavage fluid cells in mouse models of asthma. J Immunol Methods. 2004;288:111–21.PubMedCrossRef

17.

Zhou J, Kang Z, Xie Q, Liu C, Lou S, Chen Y, et al. Rapid nongenomic effects of glucocorticoids on allergic asthma reaction in the guinea pig. J Endocrinol. 2003;177:R1–4.PubMedCrossRef

18.

Pene J, Rousset F, Briere F, Chretien I, Bonnefoy JY, Spits H, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons a, g and prostaglandin E2. Proc Nat Acad Sci USA. 1988;85:6880–4.PubMedCrossRef

19.

Umetsu DT, DeKruyff RH. TH1 and TH2 CD4+ cells in human allergic diseases. J Allergy Clin Immunol. 1997;100:1–6.PubMedCrossRef

20.

Corry DB, Grunig G, Hadeiba H, Kurup VP, Warnock ML, Sheppard D, et al. Requirementsfor allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol Med. 1998;4:344–55.PubMedCrossRef

21.

Curtis JL, Byrd PK, Warnock ML, Kaltreider HB. Requirement of CD4-positive T cells for cellular recruitment to the lungs of mice in response to a particulate intratracheal antigen. J Clin Invest. 1991;88:1244–54.PubMedCrossRef

22.

Kips JC. Cytokines in asthma. Eur Respir J. 2001;18:24–33.

23.

Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175–90.PubMedCrossRef

24.

Ngoc LP, Gold DR, Tzianabos AO, Weiss ST, Celedon JC. Cytokines, allergy, and asthma. Curr Opin Allergy Clin Immunol. 2005;5:161–6.PubMedCrossRef

25.

Wills-Karp M, Luyimbazi J, Xu X, Schofield B. Interleukin-13: central mediator of allergic asthma. Science. 1998;282:2258–61.PubMedCrossRef

26.

Purkerson J, Isakson P. A two-signal model for regulation of immunoglobulin isotype switching. FASEB J. 1992;6:3245–52.PubMed

27.

Kimber I, Stone S, Dearman RJ. Assessment of the inherent allergenic potential of proteins in mice. Environ Health Perspect. 2003;111:227–31.PubMedCrossRef

28.

Abu-Ghazaleh RI, Kita H, Gleich GJ. Eosinophil activation and function in health and disease. Immunol Ser. 1992;57:137–67.PubMed

29.

Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1898;245:308–10.CrossRef

30.

Kopf M, Brombacher F, Hodgkin PD, Ramsay AJ, Milbourne EA, Dai WJ, et al. IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996;4:15–24.PubMedCrossRef

31.

Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med. 1997;185:2143–56.PubMedCrossRef

32.

Fostera PS, Martinez-Moczygembab M, Hustonb DP, Corry DB. Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease. Pharmacol Ther. 2002;94:253–64.CrossRef

33.

Toelle BG, Peat JK, Salome CM. Toward a definition of asthma for epidemiology. Am Rev Respir Dis. 1992;146:633–7.PubMed

34.

Peat J, Toelle B, Salome C. Predictive nature of bronchial responsiveness and respiratory symptoms in a one year cohort study of Sydney schoolchildren. Eur Respir J. 1993;6:662–9.PubMed

35.

Zhu Z, Homer RJ, Wang Z. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersesretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest. 1999;103:779–88.PubMedCrossRef

36.

Flohé L, Brigelius-Flohé R, Saliou C, Traber MG, Packer L. Redox regulation of NF-kappa B activation. Free Radic Biol Med. 1997;22:1115–26.PubMedCrossRef

37.

Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 1998;273:3285–90.CrossRef

Titel: Anti-inflammatory effects of ivermectin in mouse model of allergic asthma
verfasst von: Shuhan Yan
Xinxin Ci
Na Chen
Chi Chen
Xiangchao Li
Xiao Chu
Jianhua Li
Xuming Deng
Publikationsdatum: 01.06.2011
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 6/2011
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-011-0307-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background and objective

Methods and results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2011

Erratum to: Human skin penetration of a copper tripeptide in vitro as a function of skin layer

Effects of endogenous substance P expression on degranulation in RBL-2H3 cells

Urinary trypsin inhibitor attenuates lipopolysaccharide-induced acute lung injury by blocking the activation of p38 mitogen-activated protein kinase

Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor β1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation

Oxymatrine reduces neuronal cell apoptosis by inhibiting Toll-like receptor 4/nuclear factor kappa-B-dependent inflammatory responses in traumatic rat brain injury